Table 2.

Baseline characteristics and treatment profile of all patients who developed aneurysms after Everolimus eluting Xience stents

	Patient A	Patient B	Patient C	Patient D
Patient characteristics
Age	68 years	69 years	71 years	54 years
Sex	Male	Male	Female	Male
Hypertension	Yes	Yes	Yes	Yes
Diabetes mellitus	No	Yes	No	No
Lesion characteristic
Long/diffuse lesion (> 20 mm)	Yes	Yes	Yes	Yes
% Stenosis	100%	90–95%	80%	99%
Artery involved	LAD	LAD	RCA	LAD
Initial angioplasty details
Stent size deployed	2.75 × 28 mm	2.75 × 33 mm	2.5 × 38 mm	3 × 28 mm
Stent type	Xience V	Xience Prime LL	Xience Prime LL	Xience V
Metal alloy in stent	L605 cobalt chromium	L605 cobalt chromium	L605 cobalt chromium	L605 cobalt chromium
Drug polymer	Acrylate primer and a fluorinated copolymer	Acrylate primer and a fluorinated copolymer	Acrylate primer and a fluorinated copolymer	Acrylate primer and a fluorinated copolymer
Drug eluting	Everolimus	Everolimus	Everolimus	Everolimus
Post dilatation	3 mm at 15 atm	3 mm at 13 atm	2.75 mm at 16 atm	3.5 mm at 15 atm
Dual anti-platelet drugs	Ticagrelor + ecospirin	Clopidogrel + ecospirin	Clopidogrel + ecospirin	Ticagrelor + ecospirin
Patient re admission presentation
Fever	Nil	Nil	Nil	Nil
Unstable angina	Yes	Yes	Yes	Yes
Days after initial angioplasty	4 months	3.5 months	2.5 months	7 months
TLC during re-admission	6600/µL	7900/µL	9700/µL	8200/µL
Eosinophil count	600/µL	800/µL	1500/µL	800/µL
Aneurysm details	One large saccular aneurysm	Three large saccular aneurysms	Two–three small fusiform aneurysms	Two large saccular aneurysms
Arterial segment involved	Proximal LAD	Proximal LAD	Distal RCA	Left main and proximal LAD
Second admission treatment
Angioplasty	Covered stent (3.5 × 26 mm)	Covered stent (3.5 × 19 mm)	Drug eluting stent (2.75 × 23 mm)	Operative repair and grafting
Outcome	Expired	Expired	Alive	Alive